Does NELVUTAMIG Cause Immune-mediated hepatitis? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Immune-mediated hepatitis have been filed in association with NELVUTAMIG. This represents 6.5% of all adverse event reports for NELVUTAMIG.
18
Reports of Immune-mediated hepatitis with NELVUTAMIG
6.5%
of all NELVUTAMIG reports
2
Deaths
12
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From NELVUTAMIG?
Of the 18 reports, 2 (11.1%) resulted in death, 12 (66.7%) required hospitalization, and 8 (44.4%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NELVUTAMIG. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does NELVUTAMIG Cause?
Off label use (29)
Hypothyroidism (17)
Immune-mediated enterocolitis (16)
Malignant neoplasm progression (16)
Colitis (15)
Drug ineffective (14)
Immune-mediated hepatic disorder (14)
Fatigue (13)
Immune-mediated myocarditis (11)
Diarrhoea (10)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
Which NELVUTAMIG Alternatives Have Lower Immune-mediated hepatitis Risk?
NELVUTAMIG vs NEMOLIZUMAB
NELVUTAMIG vs NEMOLIZUMAB-ILTO
NELVUTAMIG vs NEOMYCIN
NELVUTAMIG vs NEORAL
NELVUTAMIG vs NEOSTIGMINE